ベータ
治験レーダーAI
治験 NCT07498686(対象:RT-QuIC)は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease 458 バイオマーカー 新規治療

募集中
治験(臨床試験)の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします!「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT07498686 は 観察研究 臨床試験 で、RT-QuIC に関するものです。現在は 募集中 で、2023年5月1日 から開始しています。458 名の参加者 の募集が計画されています。この試験は Xuanwu Hospital, Beijing によって主導され、2026年12月23日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年3月27日 です。
概要
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons,...もっと見る
公式タイトル

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease

疾患名
RT-QuIC
その他の研究識別子
  • 115
NCT番号
開始日
2023-05-01
最終更新日
2026-03-27
終了予定日
2026-12-23
目標参加者数
458
試験の種類
観察研究
状況
募集中
キーワード
PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein
群(アーム)/介入
参加グループ/群介入/治療法
Control
Control: healthy subjects,
該当なし
PD
parkinson's disease patients
該当なし
MSA
MSA: multiple system atrophy
該当なし
PSP
progressive supranuclear palsy
該当なし
主要評価項目
評価指標指標の説明時間枠
slope
slope of all Fluorescence value
From enrollment to the end of treatment at 21 weeks
MAX
Maximum fluorescence value
From enrollment to the end of treatment at 21 weeks
参加アシスタント
適格基準

対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
健康なボランティアを受け入れる
はい

- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn & Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

  • Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.
Xuanwu Hospital, Beijing logoXuanwu Hospital, Beijing
試験中央連絡先
連絡先: Weiwei YANG, Ph.D., +86 010-83198271, [email protected]
2 1カ国の場所

Beijing Municipality

Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
完了
Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Weiwei YANG, 連絡先, +86 010-83198271, [email protected]
募集中